Skip to content

Aerify3: A Potential New Treatment for Airway Inflammation in COPD

Search Clinical Trials

Trial Objectives

Treatments for chronic obstructive pulmonary disease (COPD) may still leave people experiencing wheezing, coughing, or shortness of breath. Researchers in the Aerify3 study are investigating a medication called itepekimab, which has shown some potential in earlier clinical trials to improve symptoms in those with COPD.

COPD symptoms can be worsened by inflammation in the lungs that makes it harder to breathe. Itepekimab has been shown to reduce inflammation in the body without suppressing the immune system. This trial is investigating changes in gene expression in those treated with this drug to evaluate how their lung inflammation has been reduced.

Participants will undergo two bronchoscopies within the first 12 weeks of the study, and biopsies will be taken to study gene expression during the procedures. They also will be monitored for changes of symptoms and receive blood tests to monitor
changes in the blood cells.

Who Can Participate

People with a diagnosis of pulmonary sarcoidosis, who are receiving oral prednisone treatment and have been on a clinically stable dose of oral corticosteroid for at least 4 weeks.

Age: 40-70 Gender: Any

Estimated Time Commitment

Approximately 9 clinic visits and 1 telephone visit, once every two weeks. Visits will take 1-4 hours

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Jennifer Underwood

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required